Product Approval and Commercialization - NERLYNX is currently approved in the United States for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed breast cancer and for use in combination with capecitabine for advanced HER2-positive breast cancer [21]. - As of December 31, 2024, NERLYNX has received approval in over 40 countries outside the United States, including the European Union, China, and Canada [22]. - The commercialization strategy for NERLYNX includes a direct sales force of approximately 35 specialists in the U.S. and exclusive sub-license agreements for international markets [22]. - NERLYNX was launched in July 2017 and aims to establish itself as the standard of care for extended adjuvant treatment of early stage HER2-positive breast cancer [109]. - NERLYNX received marketing authorization in the EU in August 2018 for early stage hormone receptor positive HER2-overexpressed breast cancer, and was added to China's National Reimbursement Drug List in December 2021, broadening access to more women [113][114]. - The company is actively seeking regulatory or data exclusivity in jurisdictions outside the U.S. and Europe, including Chile and Taiwan [118]. - The company is pursuing patent term extensions for U.S. Patent No. 7,399,865, which is eligible for a five-year extension, expiring December 29, 2030 [118]. - The company has a total obligation of $187.5 million in milestone payments to Pfizer, triggered by FDA approval of NERLYNX in July 2017 [131]. - The annual royalty payments to Pfizer for net sales of licensed products range from approximately 10% to 20%, reduced to a fixed rate in the low to mid-teens as per the amendment in July 2014 [132][133]. Clinical Trials and Efficacy - Neratinib demonstrated a 33% reduction in the risk of invasive disease recurrence or death compared to placebo, with a two-year disease-free survival (DFS) rate of 93.9% for the neratinib arm versus 91.6% for the placebo arm [34]. - In the ExteNET trial, neratinib showed a 27% reduction in the risk of invasive disease recurrence or death after five years, with a five-year invasive disease-free survival (iDFS) rate of 90.2% for the neratinib arm compared to 87.7% for the placebo arm [38]. - The two-year DFS rate for centrally confirmed HER2-positive patients treated with neratinib was 94.7%, compared to 90.6% for the placebo group, indicating a 49% reduction in the risk of invasive disease recurrence or death [36]. - The Phase III NALA trial enrolled 621 patients, comparing neratinib plus capecitabine to lapatinib plus capecitabine [55]. - Neratinib plus capecitabine showed a statistically significant improvement in progression-free survival (PFS) with a hazard ratio of 0.76 (p=0.0059) compared to lapatinib plus capecitabine [56]. - The median overall survival (OS) for patients treated with neratinib plus capecitabine was 21.0 months, compared to 18.7 months for those treated with lapatinib plus capecitabine [57]. - The overall cumulative incidence of CNS metastases was 22.8% for the neratinib plus capecitabine arm, compared to 29.2% for the lapatinib plus capecitabine arm (p=0.043) [58]. - In the TBCRC 022 trial, 49% of patients experienced a CNS Objective Response by composite criteria, with a median overall survival of 13.5 months [65]. Adverse Events and Management - The most frequently observed adverse event in neratinib-treated patients was diarrhea, with about 39.9% experiencing grade 3 or higher diarrhea [33]. - The incidence of grade 3 diarrhea for patients receiving neratinib dose escalation regimen 1 (DE1) was 13%, significantly lower than the historical control of 39.8% from the ExteNET trial [47]. - The median cumulative duration of grade 3 diarrhea across the CONTROL DE study cohorts was 2 to 2.5 days, compared to 5.0 days for the ExteNET trial [47]. - The proportion of patients discontinuing neratinib due to diarrhea was reduced to 3% in DE1 and 6% in DE2, compared to 17% in the ExteNET trial [47]. - The CONTROL trial is investigating the use of antidiarrheal prophylaxis or dose escalation to reduce neratinib-associated diarrhea [45]. Research and Development - The company has in-licensed alisertib, which has shown activity in various cancers and was tested in over 1,300 patients across 22 trials prior to licensing [23]. - The company aims to advance alisertib development in hormone receptor positive breast cancer and small cell lung cancer, focusing on biomarker-driven populations [24]. - Alisertib showed a response rate of 19% in chemotherapy-sensitive small cell lung cancer patients, with a duration of response of 3.1 months [78]. - In a randomized Phase II trial, alisertib plus fulvestrant had a response rate of 20.0% compared to 19.6% for alisertib alone [88]. - The Phase II trial for alisertib in extensive stage small cell lung cancer will enroll up to 60 patients, with a primary endpoint of objective response rate [84]. - Approximately 72% of small cell lung cancer patient samples had c-Myc amplifications, and 60-80% had RB1 mutations [83]. - Alisertib monotherapy in HER2-negative, hormone receptor positive breast cancer resulted in a response rate of 23% and a PFS of 7.9 months [86]. - The Phase II ALISCATM-Breast1 trial is actively enrolling patients to evaluate alisertib in combination with endocrine therapy for chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer [97]. Regulatory and Compliance - The company must comply with extensive regulatory requirements throughout the drug development process, including pre-clinical tests and clinical trials [162]. - The FDA conducts inspections of manufacturing facilities and clinical sites to ensure compliance with Good Manufacturing Practices (cGMP) and Good Clinical Practices (GCP) [175]. - The FDA has a goal of 10 months to review and act on a standard NDA for a new molecular entity, typically taking 12 months from submission [173]. - The FDA may issue a Complete Response Letter indicating deficiencies in the NDA, which may require additional clinical data or trials [176]. - The FDA offers various expedited review programs, including fast track designation, breakthrough therapy designation, priority review, and accelerated approval, aimed at expediting the drug approval process for serious diseases [181]. - Orphan Drug Designation can provide exclusivity for seven years if the product receives the first FDA approval for the designated disease [179]. - In the U.S., the FDCA provides a five-year non-patent data exclusivity period for new chemical entities, preventing other companies from submitting ANDAs during this time [189]. - In the EU, new products receive eight years of data exclusivity and an additional two years of market exclusivity, with potential extensions for new therapeutic indications [203]. Financial and Business Strategy - The company reported net income for the years ended December 31, 2024, 2023, and 2022, but cannot assure continued profitability [13]. - The company faces risks related to its single product status and limited commercial sales experience, which may impact future revenue generation [13]. - The company intends to evaluate options for commercialization of drug candidates, including joint marketing partnerships and out-licensing [24]. - The company is focused on maximizing the value of its programs while maintaining flexibility in commercialization strategies [24]. - The company relies on third parties for the formulation and manufacturing of its drug candidates, which poses risks to development and commercialization efforts [13]. - The company does not have its own manufacturing facilities and relies on third-party contractors for the production of its drug candidates, including NERLYNX and alisertib [160]. - The company anticipates establishing relationships with third-party manufacturers for commercial production if alisertib or other drug candidates obtain marketing approval [161].

Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results LOS ANGELES, Calif., Feb. 27, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Pum ...

Core Viewpoint - Puma Biotechnology, Inc. (PBYI) has experienced a significant stock rally of 24% over the past three months, contrasting with a 9.7% decline in the industry, primarily driven by improved sales of its sole marketed product, Nerlynx [1][9]. Financial Performance - PBYI updated its financial guidance for 2024, now expecting Nerlynx's product sales to be between $187 million and $190 million, an increase from the previous estimate of $183 million to $190 million [2]. - For the fourth quarter of 2024, PBYI anticipates Nerlynx product sales to be in the range of $46 million to $48 million [13]. - In the first nine months of 2024, Nerlynx generated sales of $140.8 million, with third-quarter sales exceeding management's expectations [19]. Product Development - The ALISCA-Breast1 study is currently investigating alisertib in combination with endocrine therapy for treating HR+, HER2-negative recurrent or metastatic breast cancer [4]. - If successful, alisertib could enhance PBYI's position in the anticancer drug market and reduce its reliance on Nerlynx for revenue [5]. - PBYI has in-licensed global development and commercialization rights for alisertib from Takeda and is focusing on its development for various cancer indications [10]. Market Position and Competition - PBYI remains heavily dependent on Nerlynx, as it is the only approved product in its portfolio [6][12]. - The breast cancer market presents significant commercial potential; however, Nerlynx faces intense competition from established treatments like Roche's Herceptin and Novartis' Tykerb, as well as other emerging therapies [22]. Future Outlook - The successful development of alisertib and the improving sales of Nerlynx are expected to contribute to continued upward momentum for PBYI stock in 2025 [16]. - PBYI plans to meet with the FDA regarding a potential approval pathway for alisertib based on the outcomes of the ALISCA-Breast1 study [11].

Core Insights - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls in the industry [1]. Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies [1]. - The mission is to educate investors on the scientific aspects of biotech businesses to facilitate informed decision-making [1].

Core Insights - Puma Biotechnology has initiated the phase II ALISCA-Breast1 study to evaluate alisertib for treating metastatic breast cancer [1][2] - The study focuses on hormone receptor-positive, HER2-negative recurrent or metastatic breast cancer patients previously treated with CDK 4/6 inhibitors [2] - Initial data from the study is expected in 2025, with plans for a pivotal phase III study following the determination of the optimal dose [3][4] Study Objectives and Design - The main objective of the ALISCA-Breast1 study is to determine the optimal dose of alisertib in combination with selected endocrine therapy [3] - Primary endpoints include objective response rate, duration of response, disease control rate, progression-free survival, and overall survival [6] - The company will conduct an interim analysis to investigate the safety and efficacy of the study [7] Development and Market Potential - Puma Biotechnology in-licensed alisertib from Takeda in 2022, positioning it for potential use in various cancers [8] - Alisertib shows promise in HR-positive, HER2-negative breast cancer, triple-negative breast cancer, head and neck cancer, and small cell lung cancer [9] - Successful development of alisertib could enhance the company's standing in the anticancer drug market [9] Stock Performance - Year to date, Puma Biotechnology's shares have declined by 34.4%, compared to the industry's decline of 10.9% [5]

Core Insights - Puma Biotechnology, Inc. reported third-quarter 2024 adjusted earnings of 45 cents per share, exceeding the Zacks Consensus Estimate of 35 cents, and up from 17 cents in the same quarter last year [1] - Total revenues for the third quarter were $80.5 million, surpassing the Zacks Consensus Estimate of $71 million, and reflecting a year-over-year increase of approximately 43.5% [2] Financial Performance - Product revenues from Nerlynx amounted to $56.1 million, an increase of nearly 8.7% year over year, driven by inventory increases at specialty pharmacies and distributors, and exceeding the guidance range of $50-$53 million [4] - Royalty revenues reached $24.4 million, significantly higher than the previous year, attributed to expected sales to China by PBYI's offshore partner, Pierre Fabre, and beating the model estimate of $20.9 million [6] - Total operating costs for the quarter were $58.4 million, up 22.9% year over year, while selling, general and administrative expenses decreased by 26.3% to $16.8 million [7] Market Reaction - Shares of Puma Biotechnology rose by 12.2% in after-hours trading on November 7 due to better-than-expected results and strong sales performance of Nerlynx [3] Guidance and Future Outlook - The company updated its 2024 financial guidance, now expecting Nerlynx's product sales to be in the range of $187-$190 million, and royalty revenues to be between $34-$36 million [9] - For the fourth quarter of 2024, Nerlynx product sales are anticipated to be between $46-$48 million, with expected royalty revenues of $3.5-$5 million [11] Pipeline Developments - Puma Biotechnology in-licensed global development rights to alisertib from Takeda and plans to initiate a phase II study for treating patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer later in Q4 2024 [12]

Puma Biotechnology Earnings Call Commercial Update November 7, 2024 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These s ...

Financial Data and Key Metrics Changes - Puma reported total revenue for Q3 2024 of $80.5 million, with product revenue net of $56.1 million, an increase from $44.4 million in Q2 2024 and $51.6 million in Q3 2023 [8][9] - Royalty revenue was $24.4 million in Q3 2024, compared to $2.7 million in Q2 2024 and $4.5 million in Q3 2023 [9][44] - Net income based on GAAP was $20.3 million, or $0.41 per share, compared to a net loss of $4.5 million in Q2 2024 [43] Business Line Data and Key Metrics Changes - NERLYNX sales accounted for the entirety of product revenue, with 2,723 bottles sold in Q3 2024, an increase from 2,515 bottles in Q2 2024 [10][32] - New prescriptions increased by 3% compared to Q2 2024, while total prescriptions remained flat [11][35] - The commercial team focused on increasing utilization of NERLYNX among HER2-positive early-stage breast cancer patients [28] Market Data and Key Metrics Changes - In Q3 2024, approximately 74% of NERLYNX's business flowed through the specialty pharmacy channel, consistent with 72% in Q2 2024 [31] - Ex-factory bottle sales for NERLYNX were 2,723 in Q3 2024, reflecting an 8% increase quarter-over-quarter [34] - SD demand increased by 5% quarter-over-quarter and 13% year-over-year [37] Company Strategy and Development Direction - The company is committed to exploring additional commercial assets that could leverage its existing sales force and support Alisertib [59] - Puma plans to continue evaluating several drugs for potential licensing to diversify its portfolio [26] - The company aims to maintain a positive net income while focusing on the commercialization of NERLYNX and the development of its services [50][52] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining fiscal responsibility and achieving positive net income through expense reductions [51][52] - The company anticipates net product revenue for NERLYNX in the range of $187 million to $290 million for fiscal year 2024 [46] - Management expressed commitment to addressing the unmet needs of patients battling various cancers [53] Other Important Information - The company reported cash burn of approximately $0.1 million in Q3 2024, a significant decrease from $10.3 million in Q2 2024 [49] - As of September 30, 2024, the company had approximately $97 million in cash, cash equivalents, and marketable securities [50] Q&A Session Summary Question: Thoughts on sales exceeding expectations and the role of persistence - Management attributed sales growth to promotional sensitivity and effective engagement with physicians at critical decision-making times [55][56] Question: Business development opportunities and leveraging existing sales force - Management is interested in commercial assets that can utilize the existing sales force and support Alisertib [59] Question: Sales into China and expected patterns - Management indicated that sales into China have historically been lumpy and expect this trend to continue [60] Question: Initial data in lung cancer and patient status - Management did not have specific data on the two patients with partial responses at the time of the question [62] Question: Dose exploration for Alisertib - Management confirmed that they would inform the FDA of any decisions regarding dose increases but do not anticipate needing a separate meeting [63] Question: Timeline for ALISCA-Breast trial data - Management stated that enrollment for the ALISCA-Breast trial has not started yet, affecting the timeline for data presentation [68]

Core Viewpoint - Puma Biotech reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, and showing significant growth from $0.17 per share a year ago, indicating a strong performance in the biopharmaceutical sector [1][2] Financial Performance - The company achieved revenues of $80.5 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 12.88% and increasing from $56.1 million year-over-year [2] - Over the last four quarters, Puma Biotech has exceeded consensus EPS estimates three times, demonstrating a consistent ability to outperform expectations [2] Stock Performance and Outlook - Puma Biotech shares have declined approximately 29.3% since the beginning of the year, contrasting with the S&P 500's gain of 24.3%, indicating underperformance relative to the broader market [3] - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $54.02 million, and for the current fiscal year, it is $0.43 on revenues of $216.21 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Puma Biotech belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Puma Biotech's stock performance [5]

Revenue Performance - Product revenue for Q3 2024 reached $56.136 million, a 9.9% increase from $51.592 million in Q3 2023[10] - Royalty revenue surged to $24.406 million in Q3 2024, compared to $4.524 million in Q3 2023, marking a 440.5% increase[10] - Total revenue for Q3 2024 was $80.542 million, up 43.5% from $56.116 million in Q3 2023[10] - Total revenue for the nine months ended September 30, 2024, was approximately $171.4 million, a 4.8% increase from $163.5 million in the same period of 2023[200] - Product revenue, net for the nine months ended September 30, 2024, was approximately $140.8 million, down 12.5% from $149.9 million in the same period of 2023[201] Income and Earnings - Net income for Q3 2024 was $20.317 million, compared to $5.796 million in Q3 2023, representing a 250.5% increase[11] - Basic net income per share for Q3 2024 was $0.41, up from $0.12 in Q3 2023, indicating a 241.7% increase[10] - Comprehensive income for Q3 2024 was $20.375 million, compared to $5.798 million in Q3 2023, reflecting a 251.5% increase[11] - Net income for the three months ended September 30, 2024, was $20.3 million, compared to $5.8 million for the same period in 2023, representing a 250% increase[37] - Basic net income per share for the three months ended September 30, 2024, was $0.41, up from $0.12 in the same period in 2023[38] Operating Costs and Expenses - Operating costs and expenses totaled $58.463 million in Q3 2024, an increase from $47.531 million in Q3 2023, reflecting a 22.9% rise[10] - SG&A expenses decreased by approximately $6.0 million to $16.8 million in Q3 2024, a 26.2% reduction compared to $22.8 million in Q3 2023[193] - R&D expenses rose to approximately $12.6 million in Q3 2024, up from $11.5 million in Q3 2023, primarily due to increased clinical trial expenses[194] - SG&A expenses for the nine months ended September 30, 2024, were approximately $63.5 million, an 8.9% decrease from $69.7 million in the same period of 2023[204] - R&D expenses for the nine months ended September 30, 2024, were approximately $39.8 million, an increase of $2.3 million or 6.0% compared to $37.5 million for the same period in 2023[207] Cash Flow and Liquidity - Cash provided by operating activities was approximately $23.311 million for the nine months ended September 30, 2024, up from $16.554 million in the prior year, indicating a growth of 41.0%[16] - The company has cash and cash equivalents totaling approximately $96.7 million as of September 30, 2024, which is expected to be sufficient to meet operating cash needs for at least one year[25] - The Company intends to satisfy its near-term liquidity requirements through existing cash and cash equivalents, product sales, and royalties[178] Investments and Financial Obligations - The company incurred a net cash used in investing activities of approximately $18.118 million for the nine months ended September 30, 2024, compared to $10.955 million in the same period of 2023[16] - The company has significant contractual obligations to Pfizer upon achieving certain milestones related to its products[21] - The Company is obligated to make milestone payments totaling approximately $187.5 million upon achieving certain milestones, with a one-time payment of $12.5 million triggered by worldwide net sales of $250 million in 2022[154][155] Product Development and Commercialization - The company is currently commercializing NERLYNX® for HER2-positive breast cancer and has in-licensed alisertib for potential treatment of various cancer types[17] - The company has entered into an exclusive license agreement with Takeda for the worldwide research and development rights to alisertib, enhancing its product pipeline[23] - The company expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future, highlighting its dependence on this single product[91] - As of September 30, 2024, NERLYNX has received approval in over 40 countries outside the United States for the treatment of certain patients with extended adjuvant or metastatic HER2-positive breast cancer[175] Stock and Equity - The weighted-average shares of common stock outstanding increased to 49,008,464 in Q3 2024 from 47,520,338 in Q3 2023[10] - The company has outstanding options totaling 3,850,575 and warrants of 2,116,250 as of September 30, 2024, which may impact future diluted earnings per share[36] - A total of 17,529,412 shares of the company's common stock have been reserved for issuance under the 2011 Plan as of September 30, 2024[142] - The company has 100,000,000 shares of stock authorized for issuance, all of which are common stock[139] Legal and Regulatory Matters - The Company has faced litigation regarding ANDA applications for generic versions of NERLYNX from multiple companies, including Convalife and Kelun[166][168] - The Company filed a civil lawsuit against Acebright for patent infringement related to the '789 patent, which was accepted by the Jiangsu Nanjing Intermediate People's Court[163] - The Company has appealed CNIPA's decisions regarding Acebright's ANDA for a generic version of NERLYNX, which was approved on September 12, 2023[161]